Literature DB >> 3896697

Immunostimulation by retinoic acid.

G Dennert.   

Abstract

Retinoids have been shown to inhibit tumour growth in several model systems. In this paper evidence that immune effectors are important for this effect is discussed. Injection of retinoic acid (RA) into mice before challenge with allogeneic or syngeneic tumour cells results in a strong increase in cell-mediated cytotoxicity specific for the respective tumour. This stimulation appears to be due to effects taking place before or during the induction phase rather than the effector phase of cell-mediated cytolysis. The effector cells responsible for cytotoxicity express the Thy 1 antigen, are H-2 specific and are therefore T killer cells. The induction of T cell-mediated cytotoxicity requires the participation of the lymphokine interleukin 2 (IL-2). The possibility was tested that RA directly or indirectly influences the production of IL-2 and thereby stimulates the induction of T killer cells. Results indeed show that RA-injected mice display an increased capacity to produce IL-2 upon stimulation of their splenocytes in a mixed lymphocyte reaction. It appears therefore that RA has an effect on T cells that are destined to produce IL-2 upon antigenic challenge. Since IL-2 plays a role not only in the induction of specific cytotoxic T cells but also in the induction of natural killer (NK) cells, RA was also tested in a model system in which NK cells appear to play an important protective role. Results showed that split-dose irradiated mice that lose their NK activity and subsequently develop leukaemia can be protected from leukaemogenesis either by reconstitution with NK cells or by injection with RA. The question of whether this effect is due to stimulation of immune effectors or is a direct effect on the preleukaemic cells is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896697     DOI: 10.1002/9780470720943.ch8

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  6 in total

1.  Retinoic acid prevents experimental Cushing syndrome.

Authors:  M Páez-Pereda; D Kovalovsky; U Hopfner; M Theodoropoulou; U Pagotto; E Uhl; M Losa; J Stalla; Y Grübler; C Missale; E Arzt; G K Stalla
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

2.  The effects of retinol on in vitro immunoglobulin synthesis by cord blood and adult peripheral blood mononuclear cells.

Authors:  W Wang; J L Napoli; M Ballow
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

3.  Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages.

Authors:  A J Crowle; E J Ross
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

4.  Retinoic acid inhibits in vivo interleukin-2 gene expression and T-cell activation in mice.

Authors:  Aase Ertesvag; Liv M I Austenaa; Harald Carlsen; Rune Blomhoff; Heidi Kiil Blomhoff
Journal:  Immunology       Date:  2008-09-04       Impact factor: 7.397

Review 5.  New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.

Authors:  Mariana Fuertes; Julieta Tkatch; Josefina Rosmino; Leandro Nieto; Mirtha Adriana Guitelman; Eduardo Arzt
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-24       Impact factor: 5.555

6.  Host and microbial factors in regulation of T cells in the intestine.

Authors:  Chang H Kim
Journal:  Front Immunol       Date:  2013-06-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.